|
Sep 4
|
Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences
|
|
Jun 19
|
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
|
|
May 14
|
Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments
|
|
May 13
|
Jasper Therapeutics Announces Briquilimab Development Program in Asthma
|
|
May 7
|
Jasper Therapeutics to Present at Upcoming Investor Conferences in May
|
|
Apr 2
|
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 21
|
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
|
|
Mar 19
|
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
|
|
Mar 15
|
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
|
|
Mar 4
|
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
|
|
Jan 2
|
Jasper Therapeutics, Inc. Announces Reverse Stock Split
|
|
Dec 10
|
Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023
|
|
Nov 30
|
Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria
|
|
Aug 4
|
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|